Rome, Nov 9. (Adnkronos Health) – “The role of the hospital pharmacist is evolving in a highly specialized, organized, and systematic way. In the case of multiple myeloma, for example, a significant therapeutic evolution has even led to a change in the treatment paradigm, with a growing prospect of disease chronicity and, in perspective, even cure. All this leads the hospital pharmacist to develop their profession in an increasingly specialized direction.” This was stated by Andrea Marinozzi, director of the Hospital Pharmacy of Asl 4 Teramo and national Sifo manager of the scientific-cultural area (Asc) ‘Pharmaceutical Legislation: hospital and territory’, on the occasion of the national Congress of the Italian Society of Hospital Pharmacy and Pharmaceutical Services of Health Companies, which concluded yesterday in Rome.
In this context, “it is necessary to know how to manage, coordinate, prepare, and organize the various and complex therapies available, characterized by multiple protocols and therapeutic possibilities, each with its own specificities – the expert continues – In parallel, the entire managerial, administrative, and logistical component under our responsibility also evolves: from purchases to tenders, from contract and offer management to shortage management and compounding. There are many facets that require increasingly in-depth preparation and training.”
“The management of such complex patients, in the presence of such important therapeutic innovations, especially those we are experiencing recently, requires upstream organization and a proactive downstream approach – Marinozzi continues – This is precisely why all Regions must be organized, attentive, and prepared to homogeneously and transversally welcome these new technologies. As a scientific society, we are trying to build a national organization and responsibility, which can then translate into regional coordination. The goal is to guarantee all patients the same access to care, regardless of the Region in which they reside. Clinicians must have the necessary therapeutic tools, and patients must be able to receive these treatments fairly and uniformly throughout the national territory. Unfortunately, in the current reality, and also in the recent past, this is not always the case. Each Region has its own organization and professionals who structure themselves differently. This inevitably leads to different patient management and uneven access to new technologies and therapeutic opportunities.”